文献速递疼痛医学

脊髓电刺激治疗慢性疼痛的随机试验系统综述与网络荟萃分析

Systematic review and network meta-analysis of randomized trial evidence of spinal cord stimulation for chronic pain.
PubMed 文献 · Reg Anesth Pain Med · 2026-01-06

该系统综述与网络荟萃分析纳入16项随机试验的23篇报告,比较不同脊髓电刺激(SCS)与常规药物治疗(CMM)等对慢性疼痛的疗效。结果显示所有类型SCS在疼痛强度、应答率、生活质量和部分身体功能上优于CMM,但证据确定性低至中等,且多数试验存在高偏倚风险。

要点

  • 所有类型SCS在24个月内均显著降低疼痛评分(0-10),MD范围-2.37至-5.55。
  • SCS组治疗应答(疼痛缓解≥50%)的OR为9.75至63.4,但证据确定性极低。
  • 生活质量改善在6个月时MD为0.15至0.29,证据确定性中等。

核心结论

  • 低至中等确定性证据表明,所有类型SCS治疗慢性疼痛均优于常规药物治疗。

研究设计与样本

  • 系统综述与网络荟萃分析,纳入16项平行臂随机试验的23篇报告,检索至2024年12月19日。

主要发现

  • 与CMM相比,所有类型SCS在末次随访(24个月内)显著降低疼痛强度(0-10),MD范围-2.37(95%CI -3.54至-1.20)至-5.55(95%CI -7.34至-3.76;15项试验,1479例参与者;低确定性证据)。
  • 6个月时身体功能MD范围-0.20(95%CI -10.24至9.85)至-31.04(95%CI -44.36至-17.33;8项试验,837例参与者;低确定性证据)。
  • 6个月时健康相关生活质量MD范围0.15(95%CI 0.09至0.20)至0.29(95%CI 0.20至0.37;8项试验,942例参与者;中等确定性证据)。
  • 末次随访时治疗应答(疼痛强度降低≥50%)的OR范围9.75(95%CI 4.07至23.25)至63.4(95%CI 18.76至212.55;13项试验,1887例参与者;极低确定性证据)。

临床怎么用

  • 对于慢性疼痛患者,可考虑SCS作为优于常规药物治疗的干预选择,但需结合低至中等确定性证据及高偏倚风险个体化决策。

局限性

  • 除一项试验外,所有试验均被评估为高偏倚风险。
  • 疼痛强度、身体功能和应答率的证据确定性为低至极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/IMPORTANCE: Existing systematic reviews and meta-analyses of randomized trials of spinal cord stimulation (SCS) for people with chronic pain have consistently excluded direct comparisons between different types of SCS and are therefore at major risk of publication bias. OBJECTIVE: The aim of this systematic review and network meta-analysis (NMA) was to combine both direct and indirect randomized trial evidence on treatment effects of SCS for pain intensity, physical function, and health-related quality of life (HRQoL). EVIDENCE REVIEW: MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, and WikiStim were searched from inception to December 19, 2024 for parallel-arm randomized trials comparing SCS to conventional medical management (CMM), an active intervention (including other types of SCS) or placebo for adults with chronic pain. The measure of treatment effect for the primary outcome (pain intensity) and for secondary outcomes (physical function, HRQoL) was mean difference (MD) and 95% CI, and for responder rate was OR and 95% CI. NMA was performed in a frequentist framework. FINDINGS: 23 reports of 16 unique randomized trials were included. All but one trial was assessed as having a high risk of bias. Results of NMA show significant reductions in pain intensity scores (0-10) at last follow-up (within the first 24 months) were observed with all types of SCS compared with CMM, with MD range from -2.37 (95% CI -3.54 to -1.20) to -5.55 (95% CI -7.34 to -3.76; 15 trials, 1479 participants; low certainty evidence). Improvements in physical function (MD range from -0.20, 95% CI -10.24 to 9.85) to -31.04 (95% CI -44.36 to -17.33; 8 trials, 837 participants; low certainty evidence) and HRQoL (MD range from 0.15 (95% CI 0.09 to 0.20) to 0.29 (95% CI 0.20 to 0.37; 8 trials, 942 participants; moderate certainty evidence) were observed for SCS compared with CMM at 6 months. Patients were found to have a higher likelihood to be a responder to treatment (ie, ≥50% reduction in pain intensity) with all forms of SCS in comparison to CMM at last follow-up (OR range from 9.75 (95% CI 4.07 to 23.25) to OR 63.4 (18.76 to 212.55; 13 trials, 1887 participants; very low certainty evidence). Clinically meaningful improvements were observed for pain intensity, HRQoL, and in some comparisons for physical function. CONCLUSIONS: There is low to moderate certainty of evidence that all types of SCS are superior to CMM for the management of chronic pain conditions.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Eldabe S, Nevitt S, Hunter CW, et al. Systematic review and network meta-analysis of randomized trial evidence of spinal cord stimulation for chronic pain. Reg Anesth Pain Med. 2026. PMID: 41494785. doi:10.1136/rapm-2025-107068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。